Qu Biologics

42 articles with Qu Biologics

• Dr. Matt Cahill Appointed Chief Operating Officer of Qu Biologics

  1/23/2023

  Qu Biologics Inc. is pleased to announce the appointment of Matt Cahill MBA JD PhD, as Chief Operating Officer.

• Qu Biologics and Karolinska Institute Initiate Important New Collaboration to Validate Molecular Mechanisms of Qu Biologics’ First-in-Class Immunotherapy Platform

  12/14/2022

  Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is excited to announce a new collaboration with Associate Professor Jonas Fuxe and his research team at the Karolinska Institute (KI) in Stockholm, Sweden, to characterize the molecular targets of Qu's SSI therapy at the tissue level that lead to resolution of disease.

• Qu Biologics to Receive Additional Funding to Support Innovative New Treatment to Restore Innate Immune Function in the Elderly

  10/17/2022

  Qu Biologics Inc. is pleased to announce that it is receiving advisory services and research and development funding of up to $6,659,050 from the National Research Council of Canada Industrial Research Assistance Program to support the implementation and completion of a Phase II randomized, placebo-controlled clinical trial of QBKPN SSI, a first-in-class immune modulator designed to optimize immunity and barrier function in the lungs.

• Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer

  9/26/2022

  Qu Biologics Inc. is pleased to announce it has received Health Canada clearance (No Objection Letter) and institutional-level ethics approval to proceed with a randomized placebo-controlled Phase II multicenter trial to assess the effectiveness of QBECO SSI.

• Qu Biologics to Receive Additional Funding to Launch Clinical Trial for the Restoration of Innate Immune Function in the Elderly Following Health Canada Go-Ahead

  7/20/2022

  Qu Biologics Inc. is pleased to announce it received clearance (No Objection Letter) from Health Canada to proceed with a randomized placebo-controlled clinical trial of QBKPN.

• 

  Money on the Move: March 16-22

  3/23/2022

  Most major money moves this week were related to immune therapy companies, including rounds of funding for T cell therapies, allergy therapies and immunomodulation platforms.

• Qu Biologics Closes USD$12M Equity Financing

  3/21/2022

  Qu Biologics Inc. is pleased to announce the closing of a USD$12M equity financing to enable expansion of Qu’s team, initiation of an additional three Phase 2 clinical studies, and the acceleration of Qu’s novel immunomodulation platform.

• Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress

  7/13/2021

  Qu Biologics Inc., a clinical stage biotechnology company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that data from Qu’s RESTORE clinical trial was presented at the 16th Congress of the European Crohn’s and Colitis Organization (ECCO).

• Qu Biologics Receives Additional Funding to Accelerate Clinical Development of Qu’s First-in-Class Immunotherapeutic for COVID-19 Prevention and Treatment

  6/23/2021

  Qu Biologics Inc. is pleased to announce it is receiving advisory services and additional research and development funding of up to $1,971,195 funding from the National Research Council of Canada Industrial Research Assistance Program.

• Results from Qu Biologics’ Crohn’s Disease RESTORE Trial Selected for Oral Presentation at ECCO 2021

  6/9/2021

  Qu Biologics Inc. is pleased to announce that the data from QBECO-CD-02, Qu’s Phase 2 study of QBECO SSI treatment for Crohn’s disease, was selected for an oral presentation at the 16th Congress of European Crohn’s and Colitis Organization, a leading GI conference.

• Qu Biologics Files Important New IP for the Treatment of Post-Surgical Immune Dysfunction and Prevention of Cancer Metastasis

  5/12/2021

  Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, recently expanded its patent portfolio to include the perioperative use of Qu’s SSIs to overcome immune dysfunction in patients undergoing cancer surgery.

• Positive Signals for Endoscopic and Histologic Response in Patients with Crohn’s Disease Treated with Qu Biologics’ QBECO

  1/4/2021

  Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to report positive signs of clinical, endoscopic and histologic response in subjects participating in Stage 1 of their Phase 2 RESTORE trial for the treatment of patients with moderate-to-severe Crohn’s disease. These posi

• Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform

  12/18/2020

  Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce it is receiving advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to quickly move forward the potential applic

• Qu Biologics Completes $8M Financing

  12/9/2020

  Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators, a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce an oversubscribed $8 million financing.

• Qu Biologics is pleased to announce the appointment of Karn Manhas to Qu’s Board of Directors

  8/24/2020

  Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators, a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that Karn Manhas, Founder and CEO of Terramera and agtech industry pioneer, has joined Qu Biologics’ Board of Directors.

• Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer

  8/18/2020

  VANCOUVER, British Columbia, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce approval from the Israeli Ministry of Health to proceed with their clinical trial of QBECO SSI in patients with colorectal cancer. The study, “Assessment of QBECO SSI on Immunological Parameters in the Tumor Microenvironment and Sy

• Qu Biologics publishes landmark studies showing cells of the innate immune system can be directed to target organ sites to prevent and clear pathology and infection

  4/6/2020

  Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators, a unique platform of microbial-based immunotherapies designed to restore the body’s innate immune system, has published for the first time the basis of their first-in class therapy.

• Qu Biologics Completes Enrollment in First Stage of Phase 2 Clinical Trial in Moderate to Severe Crohn’s Disease

  12/18/2019

  In this open-label first stage of a 170-patient study, 20 patients with moderate to severe Crohn’s disease will be treated for up to 52 weeks with the novel investigational agent, QBECO SSI, which is designed to restore, rather than suppress, immune function.

• Qu Biologics: Discovery of Innate Immune Mechanisms of a Novel Microbial-based Approach for the Treatment of Lung Cancer

  11/28/2017

  The company just published collaborative research with Dartmouth College detailing the mechanism of action and efficacy of Qu’s lung-targeted SSI, QBKPN, for the treatment of lung cancer.

• Qu Biologics Recruits Ms. Jennifer Archibald, Chief Financial Officer, and Mr. Alun Rees, VP, Manufacturing, to Leadership Team

  11/9/2017

  Ms. Jennifer Archibald has joined Qu Biologics in the role of Chief Financial Officer (CFO) to head up the company’s financial and accounting operations.